In hepatocellular carcinoma, combined knockdown of EZH1 and EZH2 has shown greater tumor suppression than targeting EZH2 alone, suggesting that dual inhibitors could be more effective in certain cancers [194]. The gene discussed is EZH2; the disease is hepatocellular carcinoma.